Why Did the FDA Just Ignore Safety Signals on HPV Vaccine in Women Aged 26 to 45?


Last Friday, the FDA approved of HPV vaccination of older women – at the end of a week in which a blockbuster book came out that highlights serious issues with the HPV vaccine – including troubling safety signals that the FDA knows about.

Previously, the vaccine had been approved for use ages 9-26, although scant data exists on the efficacy and safety in 9-year olds.  The FDA extended the approved use into an age group (27 to 45 years old women), some of whom will now almost certainly feel the effects of FDA’s latest flawed approval by experiencing autoimmunity, paralysis and death.

What the FDA Knows We Now Know, Too

What FDA knows is that the HPV vaccine safety trial used to approve HPV for females aged 9-26 used 1/2 of the aluminum adjuvant compared to the vaccine brought to market.

They also know that for the new age group there is a likely increase in the incidence of cervical cancer following vaccination.  Through two years of sleuthing, the authors of the book “HPV Vaccines of Trial” found that Merck informed FDA of a group that experienced “negative efficacy” – that is, an increase in the rate of pre-cancerous lesions that could lead to cervical cancer, and that the data show that if a woman is already infected or has evidence of prior infection at vaccination, combined with along with real world co-factors like smoking, they risk a 44% greater chance of developing CIN 2/3 lesions or worse.

Which age group is most likely to already have had infection?  Women over 26.

So, combined with the bombshell reveal that the product on the market is not the product that was tested, we now have the sad problem that women over the age of 26 will join the ranks of those already at risk of autoimmune disease, paralysis and death due to the HPV vaccine.

Misinformation Campaign Gets Worse

The press does not have the scientific acumen to know that their latest coverage claiming that Australia may “eliminate HPV” (New York Times, BBC) is based on a flawed modeling effort that assumes HPV vaccination confers lifelong immunity to HPV infection.  First, it does not confer lifelong immunity to the HPV types in the vaccine; second, many other types of HPV virus exist that are not targeted by the vaccine at all – including no cross-protection – that are also high-risk (see High-Risk Type Replacement)

I have just completed recording a lecture on HPV Virus, HPV Infection and the HPV vaccines, which will be available at cancercourse.com   Persistent infection appears to be a risk – and I have a hypothesis that vaccination of the most prevalent types allows the non-vaccine targeted types present in co-infection to flourish. You can preview the lecture slides at the IPAK website.

You can hear from all three authors of this extremely important book from Thursday’s Highwire Episode:


You can read the evidence yourself, see the submitted data, see the pseudo-science used by Merck to convince the FDA that the HPV vaccine is safe.  What is most unbelievable is that there are people who want to mandate this vaccine.  This vaccine’s time is up.

HPV vaccine on trial

Original source: https://jameslyonsweiler.com/2018/10/06/why-did-the-fda-just-ignore-safety-signals-on-hpv-vaccine-in-women-aged-26-to-45/

0 0 votes
Article Rating

Follow James Lyons-Weiler, PhD on:

Notify of
Inline Feedbacks
View all comments